Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) traded down 4.8% on Monday . The stock traded as low as $5.00 and last traded at $5.00. 100,200 shares traded hands during trading, an increase of 7,078% from the average session volume of 1,396 shares. The stock had previously closed at $5.25.
Idorsia Price Performance
The company has a 50-day simple moving average of $4.74 and a 200 day simple moving average of $4.33.
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Featured Stories
- Five stocks we like better than Idorsia
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
- The day the gold market broke
- What a Former CIA Agent Knows About the Coming Collapse
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
